Navigation Links
Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Date:5/8/2009

betes classified from normotension to hypertension, and to test whether this extensive subgrouping might provide additional insight for practicing physicians.

"It is essential to manage blood pressure very aggressively in diabetics because their heart attack and stroke rates are more closely related to their blood pressure levels than to their blood sugar levels," said Joseph L. Izzo, Jr., M.D., Professor of Medicine and Pharmacology at SUNY-Buffalo and Director of Medicine at the Erie County Medical Center in Buffalo. "In ROADMAP, to date, we have achieved some of the lowest BP levels ever in a clinical trial.

About ROADMAP

ROADMAP is a randomized, double-blind, placebo-controlled, parallel-group, multi-center Phase III study being conducted at 262 collaborating centers in 19 European countries. The primary goal of the study is to test the hypothesis that treatment of T2DM patients with 40 mg of olmesartan medoxomil will prevent or delay the occurrence of microalbuminuria in comparison to a regimen that excludes agents that directly block the RAS. The secondary objective is to test the hypothesis that treatment with olmesartan medoxomil has a positive effect on cardiovascular and renal morbidity and mortality.

The study involves 4,449 men and women with T2DM with normoalbuminuria (less than or equal to 35 mg albumin/g urine creatinine for women and less than or equal to 25 mg albumin/g urine creatinine for men) at the outset, and who have at least one additional cardiovascular risk factor, including patients being treated for hypertension. Patients were randomized to receive 40 mg of olmesartan medoxomil or placebo for an average of five years. Patients with hypertension were also treated at the investigator's discretion with diuretics, alpha- or beta-blockers or calcium channel antagonists to achieve a target BP of <130/80. Patients requiring treatment with an ARB or ACEi were withdr
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation
4. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
5. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
6. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
7. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
8. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
(Date:8/29/2014)... WEST JORDAN, Utah , Aug. 29, 2014 /PRNewswire/ ... Imaging Solutions, has acquired Polaris Medical Imaging, a leader ... CT scanners. This strategic acquisition allows BC Technical to ... their capabilities, specifically within MR and CT modalities. ... lower cost service," said Mark Alvarez , president ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4BC Technical Acquires Polaris Medical Imaging 2US CNS Disorders Drug Pipeline Insight 2014 2
... Reportlinker.com announces that a new market research ... Global Medical Laser Systems Industry ... This report analyzes the worldwide markets ... by the following Product Segments: Surgical Lasers, ...
... Reportlinker.com announces that a new market research ... Global Microscopes Industry ... report analyzes the worldwide markets for Microscopes ... Segments: Optical Microscopes, Charged Particle Microscopes, and ...
Cached Medicine Technology:Global Medical Laser Systems Industry 2Global Microscopes Industry 2
(Date:9/2/2014)... September 02, 2014 The Quantum ... Quantum Innovations, Inc . (QI), it has ... for MU2 Certification with a private IT security laboratory ... , The platform has Meaningful Use 1 certification status ... (7) approved and 15 pending patents. The accrediting organization ...
(Date:9/2/2014)... Kicking blog MichaelHusted.com is featuring an ... his role as a kicking coach, his kicking business, and ... to retired NFL kicker Michael Husted author of HustedKicking.com. , ... is one of the top pro free agent kickers out ... Anthony at our 2014 Pro Camp and I was impressed ...
(Date:9/2/2014)... 2 September 2014: The fact that mechanical heart valves ... by data from the ROPAC registry presented for the ... session by Professor Jolien W. Roos-Hesselink, co-chair with Professor ... found that 1.4% of pregnant women with a mechanical ... pregnancy. , The Registry Of Pregnancy And Cardiac disease ...
(Date:9/2/2014)... 02, 2014 “Harmonicas have been ... decade, primarily to help people with COPD or ... three developed systems,” says Dana Keller, PhD, co-inventor ... the goals are much the same – improved ... type of harmonica.” , The three approaches to ...
(Date:9/2/2014)... 2014 Fast hosting is a great ... compared many professional web hosting suppliers and announced that ... suppliers. , “It is hard to find a ... their competitors on hosting features, uptime, server speed and ... at affordable rates,” a manager of Top10BestSEOHosting.com says. , ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Features Interview with Anthony Cantele of Cantele Kicking on His Role as a Kicking Coach and on Becoming a National Camp Series (NCS) Associate 3Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Top10BestSEOHosting.com Recommends Fast Web Hosting Suppliers 2
... and Manufacturing Plans Approved for Neuradiab(TM) Multi- center ... Clinical Trial ... TSX: ... the development and,commercialization of cancer therapies, today announced that it has received,notification from the ...
... June 3 When Brett Waslefsky,s wife,said her job ... a school,teacher, the stresses of the job, as well ... to stay healthy. With this casual,conversation, a new kind ... Employee Vita, a web-based vitamin company,that offers occupation specific ...
... childhood pneumococcal conjugate vaccine has been a boon in ... and the medical community must not get complacent, as ... rise, say scientists at a meeting today in Boston. ... the total burden of pneumococcal disease. It targets ...
... Cancer is the Number One Cause ... MAF Canine Cancer Campaign Seeking to Treat and Cure Dogs, DENVER, ... http://www.MorrisAnimalFoundation.org, a canine,cancer exclusive of special interest to dog owners ... the number one cause,of death in dogs over the age of two. ...
... To shed unwanted pounds,Americans, spend $46 billion ... and dietitians say merely choosing the right nutrient-dense,foods ... inflammation in our,bodies, and feel more energetic. But ... healthy ingredients we,re encouraged to buy. The article, ...
... asserts passage would strip illustrators of essential rights ... educational nonprofits, LAWRENCE, Kan., June 3 ... an international organization,representing highly trained professional medical illustrators ... Orphan Works Act,of 2008" (H.R. 5889/S. 2913), pending ...
Cached Medicine News:Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 2Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 3Health News:Bradmer receives FDA approval to proceed with Phase III clinical trial 4Health News:New Vitamin Company Caters to Occupational Health Concerns 2Health News:Despite vaccine, public should not get complacent about pneumococcal disease 2Health News:Canine Cancer Web Exclusive for Dog Owners and Lovers, Presented by Morris Animal Foundation - Features Colorado State and Cornell University Veterinary Cancer Experts 2Health News:Natural Solutions Names 45 Must-Have Foods for Healthy Weight Loss 2Health News:Association of Medical Illustrators Denounces 'Orphan Works' Bills Before Congress 2
... CONMED's family of products allows you to ... generators feature proprietary Energy Synchronous Processing Technology. ... current and voltage in all operational modes. ... to sample current and voltage over 450,000 ...
... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... pacemaker family offers some ... automatic devices. Featuring the ... advanced technologies ever seen, ... incorporates the exclusive ventricular ...
Medicine Products: